Journal article

The Efficacy and Safety of Alprazolam Versus Other Benzodiazepines in the Treatment of Panic Disorder

Steven Moylan, John Staples, Stephanie Alison Ward, Jan Rogerson, Dan J Stein, Michael Berk



We performed a meta-analysis of all single- or double-blind, randomized controlled trials comparing alprazolam to another benzodiazepine in the treatment of adult patients meeting the Diagnostic and Statistical Manual of Mental Disorders, Third or Fourth Edition, criteria for panic disorder or agoraphobia with panic attacks. Eight studies met inclusion criteria, describing a total of at least 631 randomized patients. In the pooled results, there were no significant differences in efficacy between alprazolam and the comparator benzodiazepines on any of the prespecified outcomes: improvement in mean panic attack frequency (between-arm weighted mean difference of 0.6 panic attacks per week; 95%..

View full abstract

University of Melbourne Researchers


Funding Acknowledgements

Drs Moylan, Staples, Ward, and Rogerson declare no conflicts of interest. Dr Stein has received research grants and/or consultancy honoraria from AstraZeneca, Eli Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, Takeda, Tikvah, and Wyeth. Dr Berk has received research grants and support from Stanley Medical Research Institute, MBF, National Health and Medical Research Council, Beyond Blue, Geelong Medical Research Foundation, Australian Rotary Health Research Fund, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Organon, Novartis, Mayne Pharma, Servier, and AstraZeneca. He is also a consultant to AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, and Pfizer. He is a speaker at AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Cilag, Lundbeck, Organon, Pfizer, Sanofi Synthelabo, Solvay, and Wyeth.